Recent possibilities in the antiplatelet therapy

Research output: Contribution to journalReview article


The treatment of occlusive vascular disease with thrombolytic agents opened new perspectives. Whereas platelet mediated reocclusion after myocardial infarction, aprupt closure, and late restenosis after percutaneous transluminal coronary angioplasty (PTCA) remained unresolved despite enormous efforts. As far as the current status of the antiplatelet therapy is concerned, drugs (e.g. ticlopidine) revealed as effective as aspirin. Other promising agents (e.g. ketanserin) failed to become a clinically useful drug. Platelet glycoprotein IIb/IIIa receptor blockers (RGD-peptides and monoclonal antibodies) are currently in the early stages of preclinical and clinical testing and hold promise of preventing reocclusion after recanalisation in myocardial infarction and abrupt closure and late restenosis after PTCA.

Original languageEnglish
Pages (from-to)437-447
Number of pages11
Issue number6
Publication statusPublished - Dec 1 1993

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Recent possibilities in the antiplatelet therapy'. Together they form a unique fingerprint.

  • Cite this